Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report
Authors:
Open Access
- 28 March 2026
- journal article
- case report
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (7) , 100994
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancerNature Medicine, 2025
- Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenesJournal of the National Cancer Center, 2024
- An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancerFuture Oncology, 2024
- Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerFrontiers in Oncology, 2024
- ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistanceCancer Letters, 2024
- Targeting HER3 for cancer treatment: a new horizon for an old targetESMO Open, 2023
- Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic ImplicationsCancers, 2021
- Acquired Resistance to KRAS G12C Inhibition in CancerNew England Journal of Medicine, 2021